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Abstract : Pentazocine is an intravenously administered preoperative analgesic, but 
patients occasionally experience nausea and vomiting as an adverse reaction to 
this drug.  As nausea and vomiting may interfere with the patient’s postopera-
tive rest, prevention of the reaction is necessary.  This study aimed to survey 
postoperative nausea and vomiting（PONV）caused by pentazocine administered 
for catheter ablation.  Patients receiving catheter ablation often experience pain 
during venipuncture and radiofrequency application, thus they are frequently placed 
under mild to deep sedation.  Patients who underwent catheter ablation between 
February and July 2016 were analyzed retrospectively.  The preoperative analgesic 
dose and PONV were assessed.  In total, 256 subjects（177 males, mean age : 65.3
±12.9 years）were analyzed of which 185（72.3％）underwent atrial fibrillation 
ablation.  Of these, 134 subjects（52.3％）were administered 15 mg pentazocine and 
122 subjects（47.7％）were administered 30 mg pentazocine, preoperatively.  Patients 
who required additional sedative administration, as determined by the physician, 
during the procedure received either dexmedetomidine（205 subjects ; 80.1％）or 
thiopental（218 subjects ; 85.2％）.  Investigation of postoperative nausea revealed 
that 8 subjects in the 15 mg group（6.0％）and 21 subjects in the 30 mg group
（17.2％）experienced nausea, a signicantly higher percentage in the 30 mg group
（p＝0.005）.  Analysis of postoperative vomiting shows that 6 subjects in the 15 mg 
group（4.5％）and 14 subjects in the 30 mg group（11.5％）experienced postopera-
tive vomiting, indicating a higher percentage in the 30 mg group（p＝0.04）.  Fur-
thermore, the data indicate that being female is also an independent indicator of 
PONV.  The results of this study suggest a relationship between pentazocine dose 
and PONV and that the incidence of PONV is directly related to an increased 
pentazocine dose.
Key words : catheter ablation, atrial fibrillation, pentazocine, postoperative nausea 
and vomiting（PONV）
Original
1）Department of Pharmacy, Japan Red Cross Yokohama City Bay Hospital, 3-12-1, Shinyamashita, Naka-ku, Yokohama 
City, Kanagawa 231-8682, Japan.
2）Department of Clinical Pharmacy, Division of Drug Information Analytics, Showa University School of Pharmacy.
＊ To whom corresponding should be addressed.
Ryohei KUROIWA, et al104
Introduction
　Catheter ablation is the widely chosen method as a curative treatment for various arrhythmias1-3）. 
However, catheter ablation treatment is invasive and patients may experience pain or discomfort 
during venipuncture and radiofrequency（RF）application.  Inadequate sedation can result in 
patient movement due to pain or discomfort during the procedure, which can affect the accuracy 
of the 3-dimensional mapping and negatively affect the outcomes of the ablation treatment4）.  To 
minimize patient movement, appropriate management of sedation is required5-8）.  Current cath-
eter ablation treatment strategies use a combination of sedatives, such as propofol, midazolam, 
and dexmedetomidine, in conjunction with opioid analgesics, such as fentanyl and pentazocine.
　To reduce the effects of bodily movements during atrial brillation（AF）ablation, patients at 
the Japan Red Cross Yokohama City Bay Hospital（our institution）undergo deep sedation dur-
ing the procedure.  Until April 2016, the conventional method of sedation, at our institution, for 
catheter ablation used was intravenous injection of 15 mg pentazocine as a preoperative analgesic. 
After April 2016, the dose of pentazocine was increased to 30 mg, which allows for better intra-
operative management of body movement during the procedure.  However, opioid analgesics are 
known to cause nausea and vomiting9） and this postoperative nausea and vomiting（PONV）can 
interfere with the patient’s postoperative rest, a factor in the recovery process, thus, prevention 
and management PONV is essential for patient care and comfort.
　Although previous studies have examined nausea and vomiting associated with catheter abla-
tion5, 10, 11）, the status of PONV onset with different doses of pentazocine has not been investi-
gated.  In the present study, we retroactively compared the status of PONV onset caused by 2 
dosages of the analgesic pentazocine, 15 mg versus 30 mg, when used during catheter ablation.
Materials and Methods
2.1. Patients
　This single-center retrospective study analyzed the medical records of patients who had 
undergone catheter ablation for arrhythmia during the study period from February 2016 to July 
2016.  The selection criteria stipulated that only patients who received intravenous administra-
tion of pentazocine preoperatively were included in the study; patients who received additional 
intraoperative intravenous administration of pentazocine were excluded.  In cases where the same 
patient underwent multiple catheter ablation procedures during the study period, only data from 
the rst procedure was included in our analysis.  This study was approved by the Institutional 
Review Board of Japan Red Cross Yokohama City Bay Hospital（approval number : 2017-3, 
dated November 2016 to July 2017）.
2.2. Anesthesia management
　Patients received preoperative intravenous pentazocine administration prior to catheter ablation 
between February and April 2016, the pentazocine dose was 15 mg, and between May and July 
2016, the pentazocine dose was 30 mg.  Sedative administration was managed as follows : in cases 
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of ablation for supraventricular tachycardia（SVT）and premature ventricular contraction（PVC）, 
thiopental was administered as an additional sedative when necessary.  In cases of ablation 
for AF, common atrial utter（AFL）, and ventricular tachycardia（VT）, dexmedetomidine was 
continuously added intravenously and thiopental was administered intravenously as an additional 
sedative when necessary.  Medication dosages were delivered at the physician’s discretion.
2.3. Procedure
　Each patient provided written informed consent prior to the ablation procedure.  Antiarrhyth-
mic drugs were generally discontinued for at least 5 half-lives before the ablation procedure in 
all patients with SVT, PVC, and VT.  All patients with AF were orally administered an antico-
agulant, either warfarin or direct oral anticoagulants, for at least one month before AF ablation. 
Transesophageal echocardiography or enhanced computed tomography was performed just prior 
to AF ablation to rule out left atrial thrombus.
　Three or four vascular sheaths were inserted into the right femoral vein and internal jugular vein 
under lidocaine local anesthesia.  Heparin, 50-100 IU/kg of body weight, was administered after the 
insertion of vascular sheaths.  In addition, heparinized saline was also infused to maintain the acti-
vated clotting time at 300-400 seconds.  A multi-electrode mapping catheter was inserted through 
the right internal jugular vein and positioned in the coronary sinus for pacing, recording, and 
internal cardioversion.  During catheter ablation for SVT, PVC, and VT, two or three sheaths were 
inserted through the right femoral vein and positioned in the right atrium, the bundle of His site, 
and the right ventricular apex.  During AF ablation, two long sheaths were inserted through the 
right femoral vein for left atrial mapping and ablation.  In all patients, the luminal esophageal tem-
perature was measured with a thermocouple catheter inserted into the esophagus.  A single trans-
septal puncture was performed with a RF needle.  Pulmonary vein isolation was mainly performed 
using a cryoballoon catheter.  Left atrial ablation was performed with a RF catheter with a 3.5 mm 
irrigation tip under the guidance of a 3-dimensional mapping system.  An esophageal temperature 
probe was advanced into the esophagus and later adjusted to its closest proximity with the ablation 
sites along the left atrial（LA）posterior wall.  The RF power was limited to 20-25 W on the LA 
posterior wall and the RF application was truncated when the esophageal temperature increased to 
40℃.  Similarly, cryoablation was stopped when the esophageal temperature dropped below 15℃. 
During SVT, PVC, and VT, RF-guided catheter ablation with an irrigated tip was primarily per-
formed.  Cryoablation was occasionally performed if the iatrogenic risk of an atrioventricular block 
was highly suspected during slow pathway ablation or para-Hisian accessory pathway ablation.
2.4. PONV
　Nausea and vomiting symptoms were assessed if they appeared within 24 h following surgery. 
Presence of nausea was dened as an uncomfortable, sickly, or nauseated feeling.  Vomiting was 
dened as at least one instance of an oral charging of the stomach contents.  Data regarding 
nausea and vomiting episodes were extracted from medical records spanning the study period 
and utilized in our analysis.
Ryohei KUROIWA, et al106
2.5. Statistical analysis
　Statistical analysis was performed using JMPⓇPro13.0 software（SAS Institute, Tokyo, Japan）. 
Continuous variables are shown as the mean±standard deviation（SD）, and then compared using 
the Student’s t-test.  Categorical variables were analyzed using either Fisher’s exact test or chi-
squared test.  Independent variables associated with PONV were analyzed using univariate and 
multivariate analysis.  Signicant differences were set at a p-value＜ 0.05.
Results
3.1. Patient background
　Table 1 shows the patient background characteristics for the 256 patients included in the study. 
The mean age of patients was 65.3±12.9 years with 177 males（69.1％）.  One-hundred thirty-
four patients（52.3％）received 15 mg and 122 patients（47.7％）received 30 mg of intravenously 
administered pentazocine, respectively.  No other signicant differences were found between the 
two groups, including the number of patients who underwent catheter ablation for AF（p＝0.82）
or intergroup differences for any other parameter.
3.2. PONV
　Overall, there were 29 cases（11.3％）of postoperative nausea and 20 cases（7.8％）of postop-
erative vomiting.  The frequencies of nausea and vomiting, as a result of the dosage of pentazo-
cine, are shown in Figure 1.  The frequency of postoperative nausea was 6％ in the 15 mg group 
and 17.2％ in the 30 mg group, indicating a signicantly higher frequency（p＝0.005）in the 30 mg 
group.  The frequency of postoperative vomiting was 4.5％ in the 15 mg group and 11.5％ in the 
30 mg group, again indicating a signicantly higher frequency（p＝0.04）in the 30 mg group.







Age（years）  65.3±12.9  65.4±12.7  65.1±13.2 0.81a）
Male 177（69.1）  92（68.7）  85（69.7） 0.86b）
Body weight（kg）  65.8±13.7  66.0±13.5  65.5±14.0 0.79a）
BMI（kg/m2）  24.2±  4.0  24.3±  4.1  24.2±  3.9 0.83a）
Atrial fibrillation 185（72.3）  96（71.6）  89（73.0）
0.82b）
Non-atrial fibrillation  71（27.7）  38（28.4）  33（27.0）
Cryoablation±RFA 159（62.1）  76（56.7）  83（68.0）
0.06b）
RFA  97（37.9）  58（43.3）  39（32.0）
Procedure time（min） 126.9±47.5 122.4±46.0 131.9±48.7 0.11a）
Dexmedetomidine 205（80.1） 105（78.4） 100（82.0） 0.47b）
Thiopental 218（85.2） 111（82.8） 107（87.7） 0.27b）
Data given as n（％）or mean±SD. BMI ; body mass index, RFA ; radiofrequency ablation
a）Student’s t-test, b）Chi-squared test
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　Univariate analysis of the factors that affected the onset of postoperative nausea indicated 
that there were four such factors: female, pentazocine dose of 30 mg, without administration of 
dexmedetomidine, and without administration of thiopental.  We then performed multiple logistic 
regression analyses with these four factors as explanatory variables and postoperative nausea 
onset as the objective variable.  The results of multivariate analysis indicated that being female
（OR, 3.58 ; 95％ CI, 1.54-8.29 ; p＝0.003）or in the pentazocine 30 mg group（OR, 3.86 ; 95％ 
CI, 1.57-9.48 ; p＝0.003）were statistically independent risk factors（Table 2）.




（n＝227） P-value OR 95％CI P-value
Age（years）  62.5±13.9  65.6±12.8 0.22a）
Female 17（58.6）  62（27.3） ＜ 0.001b） 3.58 1.54-8.29 0.003
Body weight（kg）  63.1±11.8  66.1±13.9 0.26a）
BMI（kg/m2）  25.0±  4.6  24.1±  3.9 0.25a）
Atrial fibrillation 17（58.6） 168（74.0） 0.08b）
Cryoablation±RFA 19（65.5） 140（61.6）
0.69b）
RFA 10（34.5）  87（38.3）
Procedure time（min） 121.0±49.0 127.7±47.3 0.48a）
Pentazocine 30 mg 21（72.4） 101（44.5） 0.005b） 3.86 1.57-9.48 0.003
Dexmedetomidine 19（65.5） 186（81.9） 0.04b） 0.79 0.21-2.95 0.73
Thiopental 21（72.4） 197（86.8） 0.05c） 0.51 0.12-2.07 0.35
Data given as n（％）or mean±SD. PON ; postoperative nausea.
a）Student’s t-test, b）Chi-squared test, c）Fisher’s exact test
Fig. 1.  Frequencies of postoperative nausea and vomiting in groups 
treated with different doses of pentazocine.
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　The following ve factors were found to inuence the onset of postoperative vomiting: female, 
AF patients, administration of pentazocine 30 mg, without administration of dexmedetomidine, 
and without administration of thiopental.  As with nausea, multivariate analysis showed that 
being female（OR, 5.32 ; 95％ CI, 1.88-15.1 ; p＝0.002）or administration of pentazocine 30 mg
（OR, 3.46 ; 95％ CI, 1.19-10.0 ; p＝0.02）were statistically independent risk factors（Table 3）.
Discussion
　We found that the overall frequency of postoperative nausea following catheter ablation was 
11.3％ and the frequency of postoperative vomiting was 7.8％, inclusive of both pentazocine dos-
ages.  However, administration of pentazocine 30 mg was signicantly associated with increased 
PONV, with the postoperative nausea frequency at 17.2％ and the postoperative vomiting 
frequency at 11.5％.  Being a female patient was also demonstrated to be an independent risk 
factor for PONV.
　PONV is one of the most frequently occurring postoperative complications following general 
anesthesia.  Overall, it has been reported that the frequency of postoperative nausea is 36％
（18％-45％）and that the frequency of postoperative vomiting is 25％（16％-25.5％）12）.  Risk 
factors related to the onset rate of PONV in patients include type of anesthesia and type of 
surgery.  Patient-related risk factors for PONV are female patients, history of PONV and motion 
sickness, being a nonsmoker, and age12-15）.  Anesthesia-related risk factors include use of volatile 
anesthetics, anesthetic duration, postoperative opioid use, and use of nitrous oxide12-16）.  Surgery-
related risk factors include long procedure time, cholecystectomy, endoscopic surgery, and gyneco-
logical surgery12, 14, 15）.




（n＝236） P-value OR 95％CI P-value
Age（years）  64.8±13.0  65.3±12.9 0.85a）
Female 14（70.0）  65（27.5） ＜ 0.001b） 5.32 1.88-15.1 0.002
Body weight（kg）  61.6±12.4  66.1±13.7 0.16a）
BMI（kg/m2）  24.4±  5.3  24.2±  3.9 0.83a）
Atrial fibrillation 10（50.0） 175（74.2） 0.02b） 1.16 0.13-10.0 0.89
Cryoablation±RFA 12（60.0） 147（62.3）
0.84b）
RFA  8（40.0）  89（37.7）
Procedure time（min） 127.4±51.8 126.9±47.2 0.97a）
Pentazocine 30 mg 14（70.0） 108（45.8） 0.04b） 3.46 1.19-10.0 0.02
Dexmedetomidine 11（55.0） 194（82.2） 0.007c） 0.47 0.04-5.24 0.54
Thiopental 13（65.0） 205（86.9） 0.02c） 0.51 0.11-2.38 0.39
Data given as n（％）or mean±SD. POV ; postoperative vomiting.
a）Student’s t-test, b）Chi-squared test, c）Fisher’s exact test
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　In this study, we identied “the female sex” as a patient-related risk factor for PONV onset.  Sim-
ilarly, Honkavaara et al.17） and Beattie et al.18） reporting that menstruation increases the risk of PONV. 
However, there have also been conicting studies reporting that there is no relationship between 
the menstrual cycle and PONV19, 20）.  Thus, the relationship between PONV and female hormones 
remains unclear.  Finally, low body weight was not found to be related to the onset of PONV.
　Damage caused to the periesophageal vagal nerve during ablation of the posterior wall of 
the left atrium is thought to cause periesophageal vagal nerve paralysis21-23）.  It is believed that 
this damage results in pyloric spasms and reduces gastric motility that may result in nausea 
and vomiting.  However, in the present study, there were no signicant differences found in AF 
patients receiving 15 mg or 30 mg pentazocine.
　According to a report described by Tyndall et al., the frequency of nausea following RF abla-
tion is 22％ and the frequency of vomiting is 13％10）.  These results show even higher frequen-
cies than those found in our study.  We postulate that these differences are due to differences 
in anesthesia-related risk factors, as the study by Tyndall et al.  included fentanyl in anesthesia 
management10）.  A retrospective study of PONV associated with the combined use of fentanyl or 
pentazocine and general venous anesthesia with propofol reported that there was no signicant 
difference in the frequency of PONV between fentanyl and pentazocine24）.  However, the authors 
attributed the non-signicant difference to the high percentage of female patients in the fentanyl 
group.  Fentanyl might lead to higher PONV frequency than that caused by pentazocine.
　Pentazocine is easier to use than fentanyl because of pharmaceutical regulations regarding its 
administration.  Use of pentazocine in catheter ablation for AF has been previously reported6, 8）. 
However, these studies did not include data for nausea and vomiting frequency.  To our knowl-
edge, the present study is the rst to report the frequency of PONV caused by pentazocine in 
patients who underwent catheter ablation.
　The mechanism of nausea and vomiting due to opioids remains unknown, but it is thought 
that they cause direct stimulation of the chemoreceptor trigger zone, inhibit gastrointestinal tract 
motility, and stimulate the vestibular apparatus25-27）.  Pentazocine causes delayed emptying of gas-
tric contents and delayed gastrointestinal transit in rats, but selective kappa agonists do not cause 
these side effects.  Therefore, it is assumed that pentazocine affects gastrointestinal functions 
through an off-target mechanism other than the opioid receptors and occurrence of PONV is a 
result of pentazocine’s effect on these other site（s）28）.  Currently, there are no high-quality clini-
cal studies on antiemetics for opioid-induced nausea and vomiting, dopamine receptor antagonists 
and prokinetic agents, or antihistamines based on mechanism of action.  One of the limitations 
of our study was the fact that it was a retrospective study that utilized patient medical records ;  
thus, we have been not able to evaluate the analgesic effect of pentazocine dose.
　The results of the present study suggest a relationship between PONV onset and pentazocine. 
It was found that the onset frequency of PONV with pentazocine is dose dependent.  In conclu-
sion, the dosage of pentazocine should be carefully selected according to the degree of surgery 
and addition of antiemetic drugs should be considered for female patients receiving more than 
30 mg pentazocine.
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